[Robert: paste actual Google Review quote — filtered to mention this page's topic]
[Robert: First name + initial]
[Robert: month year of review]
SURMOUNT-1 changed obesity medicine. Tirzepatide (the active molecule in Mounjaro and Zepbound) achieved 20.9 percent mean body-weight loss at the 15-milligram weekly dose over 72 weeks. The Phase 3 randomized controlled trial enrolled 2,539 adults with obesity and was published in the New England Journal of Medicine in June 2022 (Jastreboff AM et al, NEJM 2022;387:205-216). This guide walks through trial design, primary results, side-effect profile, and follow-on trials.
Treatments supervised by Dr. Kenika Norrachetdecha
Medical Director · Thai License #72509
● Mon–Sat 8 AM–6 PM · Online consults daily · Reply in 2 Min
Personal consultation included with every program
That's −17.8 kg — you'd weigh .
Based on the 20.9% trial-mean. Individual outcomes vary.SURMOUNT-1 is the phase-3 registration trial for tirzepatide in adults with obesity. It set the bar for weight-loss efficacy in modern obesity pharmacotherapy.
Adults with obesity but without diabetes — a cleaner population than diabetes trials, designed to isolate the weight-loss effect.
All three active arms titrated identically over 20 weeks before reaching maintenance. Weekly subcutaneous injection throughout.
Weekly subcutaneous. Titrated from 2.5 mg over 20 weeks, then maintained for 52 weeks.
Weekly subcutaneous. 20-week step-up: 2.5 → 5 → 7.5 → 10 mg.
Weekly subcutaneous. Full titration ladder: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg.
Dose-dependent weight loss across all three tirzepatide arms, with the 15 mg arm reaching the largest mean reduction observed in a phase-3 obesity trial at time of publication.
The safety signal in SURMOUNT-1 was consistent with the broader GLP-1 / GIP class — predominantly transient gastrointestinal events. No new safety signals emerged.
Three observations stood out when SURMOUNT-1 was published in NEJM in 2022, and they still shape how Dr. Kenika selects therapy today.
The 20.9% reduction at 15 mg was, at time of publication, the largest mean weight loss observed in a phase-3 obesity trial — closing in on bariatric-surgery effect sizes.
Clear, monotonic dose-response across 5 / 10 / 15 mg arms supports individualised titration to tolerance rather than treating "one dose fits all".
SURMOUNT-1 established tirzepatide (dual GIP + GLP-1 agonist) as the most efficacious approved therapy for weight reduction in adults without diabetes.
Pick your treatment, enter your weights, see your trajectory. All data from peer-reviewed clinical trials. Individual outcomes vary — final program plan determined in private consultation.
Your trajectory · based on clinical-trial mean
SURMOUNT-1 reference: Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. Follow-on trials: SURMOUNT-2 (T2D, -14.7 percent), SURMOUNT-3 (lifestyle-responder maintenance, +18.4 percent additional loss with tirzepatide vs +2.5 percent regain on placebo), SURMOUNT-4 (continued vs withdrawal, 5.5 percent additional loss vs 14 percent regain). All trials published in NEJM 2023-2025.
Each program is personalized based on your profile, medical history, and goals.
Step 1 of 5
Step 2 of 5
Select all that apply, or "None of these"
Step 3 of 5
Confidential — only your doctor sees this
Step 4 of 5
Step 5 of 5
Dr. Kenika's recommendation for you
Your access
—
Our actual clinic · Real photos
Authentic medications. Direct access to Dr. Kenika. Comprehensive metabolic care beyond GLP-1 alone.
Authentic Medications
Mounjaro, Zepbound (Eli Lilly), Wegovy, Ozempic, Saxenda (Novo Nordisk) — all sourced through the licensed Thai pharmaceutical supply chain.
Direct Doctor Access
WhatsApp Dr. Kenika directly. Every GLP-1 prescription personally supervised by the Medical Director.
Beyond GLP-1
Multi-modal metabolic care: GLP-1 plus hormone optimization, IV recovery, and advanced peptide protocols.
In Thailand for treatment? Want to discuss whether SURMOUNT-1 data applies to your case? Book a Pattaya in-person consultation with our medical team — walk-ins welcome.
SURMOUNT-1 is a Phase 3 randomized controlled trial of tirzepatide (Mounjaro / Zepbound) for chronic weight management in adults with obesity. Published in the New England Journal of Medicine, June 2022 (Jastreboff AM et al, NEJM 2022;387:205-216).
2,539 adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) plus one weight-related condition, EXCLUDING type 2 diabetes. Mean baseline weight 105 kg, mean BMI 38. 67.5% female, 70.6% white. Most patients had at least one comorbidity.
Three tirzepatide doses (5 mg, 10 mg, 15 mg weekly subcutaneous injection) vs placebo. All arms included lifestyle counseling. Treatment duration: 72 weeks with 88-week safety follow-up.
Mean percent change in body weight at week 72: −15.0% (5 mg), −19.5% (10 mg), −20.9% (15 mg), vs −3.1% (placebo). All tirzepatide arms statistically superior to placebo (P<0.001). Body weight reductions ≥5% in 85–91% of tirzepatide-treated patients vs 35% on placebo.
Most common: nausea (24.6–33.0% across doses), diarrhea (18.7–23.0%), constipation (11.7–17.1%), vomiting (8.3–12.2%). Most were mild-to-moderate. Discontinuation due to adverse events: 4.3–7.1% (tirzepatide) vs 2.6% (placebo). Treatment-emergent hypoglycemia was rare.
Yes. SURMOUNT-2 (T2D patients, 2023): −14.7% at 15 mg, 72 weeks. SURMOUNT-3 (lifestyle responders, 2023): 18.4% additional weight loss with tirzepatide vs 2.5% gained on placebo. SURMOUNT-4 (maintenance): 5.5% additional loss with continued treatment vs 14% regain on placebo.
STEP-1 (semaglutide 2.4 mg) showed 14.9% weight loss at 68 weeks. SURMOUNT-1 (tirzepatide 15 mg) showed 20.9% at 72 weeks. Tirzepatide produced ~40% greater weight loss in similar populations. SURMOUNT-5 (2025) confirmed this in a direct head-to-head trial.
Randomized, double-blind, placebo-controlled, parallel-group. 1:1:1:1 randomization to placebo or three tirzepatide doses. Dose-escalation over 20 weeks to maintenance dose, then maintained through week 72. All participants received intensive lifestyle counseling.
Licensed
Thai Pharmacy
Pharmaceutical
Grade
Doctor
Supervised
Same-Day
Care
Real reviews from real patients on Google Business Profile. Currently 5.0 ★ from 15 verified reviews — and growing. Reviews are updated regularly.
[Robert: paste actual Google Review quote — filtered to mention this page's topic]
[Robert: paste actual Google Review quote — filtered to mention this page's topic]
[Robert: paste actual Google Review quote — filtered to mention this page's topic]
Peer-reviewed primary sources, FDA prescribing information, and manufacturer documentation.
Additional clinical questions are discussed during your private consultation with Dr. Kenika.
Direct access to Dr. Kenika. Authentic medications. Three access points across Thailand.
Personal medical supervision · Cancel anytime · Authentic medications from Eli Lilly and Novo Nordisk
Book via WhatsApp · Free eligibility check
Each GLP-1 protocol has a different mechanism, trial profile, and outcome ceiling. Compare or explore by location.
Eli Lilly's dual GIP/GLP-1 agonist. Highest trial-mean of any approved GLP-1. Best fit for goals above 15%.
See program →
Novo Nordisk's most-prescribed GLP-1. Excellent track record for goals up to 15%. Built-in outcome estimator.
See program →
Investigational GLP-1/GIP/Glucagon triple agonist. Highest documented mean reduction. Private-consultation program.
See program →
In-person consultation, baseline labs, and same-week start. Walk-in or appointment. Most international patients begin here.
See clinic →